Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial

Jennifer L Sherr,Bruce W Bode,Gregory P Forlenza,Lori M Laffel,Melissa J Schoelwer,Bruce A Buckingham,Amy B Criego,Daniel J DeSalvo,Sarah A MacLeish,David W Hansen,Trang T Ly,Omnipod 5 in Preschoolers Study Group:,Kate Weyman,Eileen Tichy,Michelle VanName,Michelle Brei,Melinda Zgorski,Amy Steffen,Lori Carria,Anna Busby,R Paul Wadwa,Robert Slover,Erin Cobry,Laurel Messer,Elvira Isganaitis,Louise Ambler-Osborn,Emily Freiner,Christine Turcotte,Lisa Volkening,Melissa Schoelwer,Sue A Brown,Katie Krauthause,Emma Emory,Mary Oliveri,Laya Ekhlaspour,Ryan Kingman,Betsy L Schwartz,Laura M Gandrud,Aimee Grieme,Jamie Hyatt,Siripoom McKay,Kylie DeLaO,Carolina Villegas,Jamie R Wood,Beth A Kaminski,Terri Casey,Wendy Campbell,Kim Behm,Ramon Adams,Sheri L Stone,Suzan Bzdick,Jane Bulger,Lynn Agostini,Sarah Doolittle,Kaisa Kivilaid,Krista Kleve,Bonnie Dumais,Todd Vienneau,Lauren M Huyett,Joon Bok Lee,Jason O'Connor,Eric Benjamin
DOI: https://doi.org/10.2337/dc21-2359
2022-08-01
Diabetes Care
Abstract:Objective: Very young children with type 1 diabetes often struggle to achieve glycemic targets, putting them at risk for long-term complications and creating an immense management burden for caregivers. We conducted the first evaluation of the Omnipod 5 Automated Insulin Delivery System in this population. Research design and methods: A total of 80 children aged 2.0-5.9 years used the investigational system in a single-arm study for 13 weeks following 14 days of baseline data collection with their usual therapy. Results: There were no episodes of severe hypoglycemia or diabetic ketoacidosis. By study end, HbA1c decreased by 0.55% (6.0 mmol/mol) (P < 0.0001). Time with sensor glucose levels in target range 70-180 mg/dL increased by 10.9%, or 2.6 h/day (P < 0.0001), while time with levels <70 mg/dL declined by median 0.27% (P = 0.0204). Conclusions: Use of the automated insulin delivery system was safe, and participants experienced improved glycemic measures and reduced hypoglycemia during the study phase compared with baseline.
What problem does this paper attempt to address?